These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16557738)

  • 1. Preparation of cholera vaccines by fluorocarbon extraction of cholera Vibrio suspensions.
    Altieri PL; Berman S; Groffinger A; Lowenthal JP
    Infect Immun; 1970 Apr; 1(4):334-7. PubMed ID: 16557738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective activity of cholera vaccines against E1 Tor cholera vibrios.
    PITTMAN M; FEELEY JC
    Bull World Health Organ; 1963; 28(3):379-83. PubMed ID: 13943861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective antigens from El Tor vibrios. 1. The preparation and properties of a purified protective antigen from an El Tor vibrio (Ogawa subtype).
    Watanabe Y; Verwey WF
    Bull World Health Organ; 1965; 32(6):809-21. PubMed ID: 5294306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.
    Svennerholm AM
    Int Arch Allergy Appl Immunol; 1975; 49(4):434-52. PubMed ID: 808500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.
    Gupta RK; Szu SC; Finkelstein RA; Robbins JB
    Infect Immun; 1992 Aug; 60(8):3201-8. PubMed ID: 1639490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and laboratory testing of plain and aluminum hydroxide-adsorbed cholera vaccines used in a field trial in Indonesia.
    Joó I; Csizér Z
    Bull World Health Organ; 1978; 56(4):615-8. PubMed ID: 310362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Systemic immunity of experimental animals immunized with cholera vaccines].
    Genova IuG; Bogatinov VT; Manakhilov RB; Kostova EF
    Zh Mikrobiol Epidemiol Immunobiol; 1987 Nov; (11):41-4. PubMed ID: 3434048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies on the protective value of different antigenic preparations from cholera vibrios.
    Sanyal SC; Narayanaswami A; Mukerjee S
    Indian J Med Res; 1969 Sep; 57(9):1621-8. PubMed ID: 5369787
    [No Abstract]   [Full Text] [Related]  

  • 9. Corresponding type-specificity of vibriocidal and agglutinating activities of Vibrio cholerae antisera: relevance to vaccine immunogenicity.
    Preston NW
    Epidemiol Infect; 1993 Jun; 110(3):489-97. PubMed ID: 8519314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines.
    Kim KW; Jeong S; Ahn KB; Yang JS; Yun CH; Han SH
    J Microbiol; 2017 Dec; 55(12):973-978. PubMed ID: 29214494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
    Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM
    Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of the vibriocidal antibody response to live oral cholera vaccines.
    Wasserman SS; Losonsky GA; Noriega F; Tacket CO; Castañeda E; Levine MM
    Vaccine; 1994 Aug; 12(11):1000-3. PubMed ID: 7975839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1996 Oct; 14(15):1459-65. PubMed ID: 8994322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1.
    Qadri F; Mohi G; Hossain J; Azim T; Khan AM; Salam MA; Sack RB; Albert MJ; Svennerholm AM
    Clin Diagn Lab Immunol; 1995 Nov; 2(6):685-8. PubMed ID: 8574829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and laboratory tests of oil-adjuvant cholera vaccine.
    Ogonuki H; Hashizume S; Takashashi B
    Bull World Health Organ; 1967; 37(5):729-36. PubMed ID: 5300875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses in rabbits to injections of whole cell, flagella, and flagellin preparations of cholera and noncholera vibrios.
    Smith HL
    Appl Microbiol; 1974 Feb; 27(2):375-8. PubMed ID: 4823423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J; Mazumder R; Srivastava R; Srivastava BS
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new vaccinating antigenic fraction obtained from "Vibrio cholerae" II. Biological properties of the Ch1+2 fraction compared with the bacterial vaccine (author's transl)].
    Dobin A; Wiart J
    Ann Microbiol (Paris); 1975 Jan; 126(1):45-56. PubMed ID: 811147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.